Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2022 Earnings Conference Call March 13, 2023 4:30 PM ET

Company Participants

Philip Taylor - Investor Relations, Gilmartin Group

Paul Badawi - Chief Executive Officer

Jim Rodberg - Interim Chief Financial Officer

Tom Huang - Head of Corporate Strategy

Conference Call Participants

Thomas Stephan - Stifel Financial Corp.

Craig Bijou - Bank of America Securities, Inc.

Joanne Wuensch - Citi

Cecilia Furlong - Morgan Stanley

Margaret Kaczor - William Blair

Matthew O'Brien - Piper Sandler

David Saxon - Needham & Company

Operator

Hello, and welcome to Sight Sciences Fourth Quarter 2022 Earnings Results. At this time, all participants are in listen-only mode. After the speaker’s presentation, there will be a question-and-answer session. [Operator instructions]

I would now like to hand the conference over to Trip Taylor of Investor Relations. You may begin.

Philip Taylor

Thank you for participating in today’s call. Presenting today are Sight Sciences’ Co-Founder and Chief Executive Officer, Paul Badawi; Interim Chief Financial Officer, Jim Rodberg; and Head of Corporate Strategy, Tom Huang. Earlier today, Sight Sciences released financial results for the 3 months and full year ended December 31, 2022. A copy of the press release is available on the company’s website at investors.sightsciences.com.

I’d like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of the federal securities laws. Those include statements related to Sight Sciences' anticipated financial performance and operating results, market opportunity, the future impact of supply chain disruptions, business strategy, and plans for developing and marketing new products.

Forward-looking statements are based on estimates and assumptions as of today and are neither promises nor guarantees and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements.

A description of some of the risks and uncertainties that could cause actual results to differ materially from those indicated by the forward-looking statements on this call can be found in the Risk Factors section of the Annual Report on Form 10-K that was filed today and other filings with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law.

I will now turn the call over to Paul.

Paul Badawi

Thanks, Trip. In our first full year as a public company, we made great strides fulfilling our mission to improve the lives of patients with glaucoma and dry eye. We are grateful for the trust and partnership our customers, physicians and patients have placed in us. In 2022, we grew total revenue by 46% to $71.3 million and executed our commercial and operational initiative to further solidify our position as the innovation and efficacy leader in MIGS and dry eye.